Cargando…
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and ele...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/ https://www.ncbi.nlm.nih.gov/pubmed/20234778 |
_version_ | 1782178632322514944 |
---|---|
author | Vergara-Jimenez, Jennifer Tricoci, Pierluigi |
author_facet | Vergara-Jimenez, Jennifer Tricoci, Pierluigi |
author_sort | Vergara-Jimenez, Jennifer |
collection | PubMed |
description | Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and elective PCI. This large amount of information provides a clear efficacy and safety profile of the drug, although a few questions on the use of abciximab still exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic medications. In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI. |
format | Text |
id | pubmed-2835553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28355532010-03-16 Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention Vergara-Jimenez, Jennifer Tricoci, Pierluigi Vasc Health Risk Manag Review Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and elective PCI. This large amount of information provides a clear efficacy and safety profile of the drug, although a few questions on the use of abciximab still exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic medications. In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI. Dove Medical Press 2010 2010-03-03 /pmc/articles/PMC2835553/ /pubmed/20234778 Text en © 2010 Vergara-Jimenez and Tricoci, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Vergara-Jimenez, Jennifer Tricoci, Pierluigi Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
title | Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
title_full | Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
title_fullStr | Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
title_full_unstemmed | Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
title_short | Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
title_sort | safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/ https://www.ncbi.nlm.nih.gov/pubmed/20234778 |
work_keys_str_mv | AT vergarajimenezjennifer safetyandefficacyofabciximabasanadjuncttopercutaneouscoronaryintervention AT tricocipierluigi safetyandefficacyofabciximabasanadjuncttopercutaneouscoronaryintervention |